REATA PHARMACEUTICALS, INC.

(RETA)
  Report
Delayed Nasdaq  -  04:00 2022-08-11 pm EDT
20.96 USD   -2.78%
08/09Baird Lowers Reata Pharmaceuticals' Price Target to $27 From $37, Maintains Market Neutral Rating
MT
08/09Reata Pharmaceuticals Announces Three Month Extension of the Review Period for New Drug Application for Omaveloxolone for the Treatment of Friedreich's Ataxia
BU
08/09Reata Pharmaceuticals Announces Three Month Extension of the Review Period for New Drug Application for Omaveloxolone for the Treatment of Friedreich’s Ataxia
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Sector Update: Health Care Stocks Decline Premarket Wednesday

05/19/2021 | 09:20am EDT


© MT Newswires 2021
Stocks mentioned in the article
ChangeLast1st jan.
111, INC. -2.53% 2.31 Delayed Quote.-34.00%
NASDAQ COMPOSITE -0.58% 12779.91 Real-time Quote.-17.83%
REATA PHARMACEUTICALS, INC. -2.78% 20.96 Delayed Quote.-20.52%
SO-YOUNG INTERNATIONAL INC. 0.30% 0.9412 Delayed Quote.-70.50%
All news about REATA PHARMACEUTICALS, INC.
08/09Baird Lowers Reata Pharmaceuticals' Price Target to $27 From $37, Maintains Market Neut..
MT
08/09Reata Pharmaceuticals Announces Three Month Extension of the Review Period for New Drug..
BU
08/09Reata Pharmaceuticals Announces Three Month Extension of the Review Period for New Drug..
CI
08/09Goldman Sachs Adjusts Price Target on Reata Pharmaceuticals to $76 From $73, Reiterates..
MT
08/08Reata Shares Down 33%; Reports 2Q and Details of FDA Meeting
DJ
08/08Cantor Fitzgerald Lowers Price Target for Reata Pharmaceuticals to $47 From $68, Mainta..
MT
08/08SECTOR UPDATE : Health Care Stocks Getting Late Boost Back to Positive Ground
MT
08/08SECTOR UPDATE : Health Care
MT
08/08Top Midday Decliners
MT
08/08Wall Street Set to Open in Positive Territory as Strong Employment Data Allay Recession..
MT
More news
Analyst Recommendations on REATA PHARMACEUTICALS, INC.
More recommendations
Financials (USD)
Sales 2022 3,18 M - -
Net income 2022 -307 M - -
Net cash 2022 218 M - -
P/E ratio 2022 -2,49x
Yield 2022 -
Capitalization 765 M 765 M -
EV / Sales 2022 172x
EV / Sales 2023 23,0x
Nbr of Employees 348
Free-Float 82,9%
Chart REATA PHARMACEUTICALS, INC.
Duration : Period :
Reata Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends REATA PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 9
Last Close Price 20,96 $
Average target price 50,67 $
Spread / Average Target 142%
EPS Revisions
Managers and Directors
J. Warren Huff Chairman & Chief Executive Officer
Manmeet Singh Soni President, Chief Operating & Financial Officer
W. Christian Wigley Chief Scientific Officer & Senior Vice President
Edmund Doherty Vice President-Medical Affairs
Samina Khan Chief Medical Officer & Senior Vice President
Sector and Competitors
1st jan.Capi. (M$)
REATA PHARMACEUTICALS, INC.-20.52%765
GILEAD SCIENCES, INC.-13.99%78 273
VERTEX PHARMACEUTICALS33.04%74 927
REGENERON PHARMACEUTICALS, INC.-1.21%66 700
WUXI APPTEC CO., LTD.-20.30%40 674
BIONTECH SE-38.48%38 540